Rockefeller Capital Management’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $946K | Sell |
15,063
-616
| -4% | -$42.9K | ﹤0.01% | 1635 |
|
|
2025
Q4 | $1.04M | Buy |
15,679
+938
| +6% | +$60.6K | ﹤0.01% | 1545 |
|
|
2025
Q3 | $992K | Buy |
14,741
+4,701
| +47% | +$372K | ﹤0.01% | 1429 |
|
|
2025
Q2 | $876K | Buy |
+10,040
| New | +$787K | ﹤0.01% | 1377 |
|
|
2025
Q1 | – | Sell |
-12,502
| Closed | -$981K | – | 1677 |
|
|
2024
Q4 | $981K | Sell |
12,502
-2,892
| -19% | -$214K | ﹤0.01% | 1258 |
|
|
2024
Q3 | $1.04M | Sell |
15,394
-100,313
| -87% | -$8.24M | ﹤0.01% | 1213 |
|
|
2024
Q2 | $13.1M | Sell |
115,707
-5,912
| -5% | -$747K | 0.04% | 426 |
|
|
2024
Q1 | $16.9M | Sell |
121,619
-10,441
| -8% | -$1.31M | 0.05% | 370 |
|
|
2023
Q4 | $16.4M | Buy |
132,060
+2,550
| +2% | +$261K | 0.05% | 335 |
|
|
2023
Q3 | $12.1M | Buy |
129,510
+6,777
| +6% | +$764K | 0.05% | 374 |
|
|
2023
Q2 | $15.7M | Buy |
122,733
+1,646
| +1% | +$199K | 0.06% | 330 |
|
|
2023
Q1 | $14.1M | Buy |
121,087
+1,905
| +2% | +$213K | 0.06% | 344 |
|
|
2022
Q4 | $13.5M | Buy |
119,182
+1,707
| +1% | +$187K | 0.07% | 306 |
|
|
2022
Q3 | $9.46M | Buy |
117,475
+779
| +0.7% | +$66K | 0.05% | 370 |
|
|
2022
Q2 | $8.7M | Sell |
116,696
-1,212
| -1% | -$111K | 0.05% | 379 |
|
|
2022
Q1 | $15.1M | Buy |
117,908
+1,704
| +1% | +$186K | 0.07% | 269 |
|
|
2021
Q4 | $15.6M | Buy |
116,204
+3,924
| +3% | +$564K | 0.07% | 261 |
|
|
2021
Q3 | $15.3M | Buy |
112,280
+1,780
| +2% | +$224K | 0.08% | 253 |
|
|
2021
Q2 | $11.8M | Sell |
110,500
-2,244
| -2% | -$216K | 0.07% | 274 |
|
|
2021
Q1 | $10.1M | Buy |
112,744
+7,296
| +7% | +$685K | 0.07% | 248 |
|
|
2020
Q4 | $9.75M | Sell |
105,448
-16,068
| -13% | -$1.43M | 0.07% | 229 |
|
|
2020
Q3 | $12.5M | Buy |
121,516
+5,388
| +5% | +$563K | 0.12% | 176 |
|
|
2020
Q2 | $11.8M | Sell |
116,128
-14,588
| -11% | -$1.3M | 0.12% | 168 |
|
|
2020
Q1 | $8.8M | Sell |
130,716
-753,724
| -85% | -$46.9M | 0.12% | 171 |
|
|
2019
Q4 | $48.4M | Sell |
884,440
-80,604
| -8% | -$3.82M | 0.6% | 38 |
|
|
2019
Q3 | $36M | Sell |
965,044
-395,352
| -29% | -$15.4M | 0.49% | 47 |
|
|
2019
Q2 | $51M | Buy |
1,360,396
+3,236
| +0.2% | +$102K | 0.71% | 36 |
|
|
2019
Q1 | $40.4M | Sell |
1,357,160
-547,488
| -29% | -$19.2M | 0.58% | 41 |
|
|
2018
Q4 | $57M | Buy |
1,904,648
+9,392
| +0.5% | +$298K | 1% | 26 |
|
|
2018
Q3 | $67.8M | Sell |
1,895,256
-1,681,192
| -47% | -$52.1M | 1.03% | 31 |
|
|
2018
Q2 | $84.9M | Sell |
3,576,448
-44,420
| -1% | -$942K | 1.38% | 25 |
|
|
2018
Q1 | $67.1M | Buy |
+3,620,868
| New | +$53.5M | 1.11% | 28 |
|
Other funds holding DXCM
VCM
VPM
Rockefeller Capital Management's DXCM Position: Q1 2026 in Review
Rockefeller Capital Management reduced its DexCom (DXCM) stake by 3.9% in Q1 2026, selling an estimated $42.9K and leaving 15,063 shares worth $946K. The position accounts for ﹤0.01% of the portfolio, ranked #1635.
Rockefeller Capital Management first reported a position in DXCM in Q1 2018 and has held it in 32 quarters since. The position peaked at $84.9M in Q2 2018. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Rockefeller Capital Management held 15,063 shares of DexCom worth $946K as of Q1 2026.
- Rockefeller Capital Management sold 616 DexCom shares in Q1 2026, an estimated $42.9K.
- DexCom made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1635 holding.
- Rockefeller Capital Management first reported a position in DexCom in Q1 2018 and has held it in 32 quarters since.
- Rockefeller Capital Management's DexCom position peaked at $84.9M in Q2 2018.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.